PolyPid (PYPD) News
NASDAQ: PYPDHealth CareMedical/Dental InstrumentsUSD
6.12-0.43 (-6.56%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PYPD news summary
We found 8 recent headlines mentioning PolyPid (PYPD): 0 in the past week and 6 in the past 30 days, most often from Nasdaq, GlobeNewswire. PYPD is making an outsized move today, down 6.56% at $6.12, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "PolyPid Ltd. Reports Third Quarter 2026 Financial Results and Updates on D-PLEX₁₀₀ Regulatory Progress", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest PolyPid headlines
- PolyPid Ltd. Reports Third Quarter 2026 Financial Results and Updates on D-PLEX₁₀₀ Regulatory ProgressPolyPid Ltd. reported a net loss of $5.8 million, or $(0.24) per share, for the three months ended September 30, 2026, compared to a net loss of $7.5 million, or $(0.37) per share, in the three-month…Nasdaq
- PolyPid: 3 Key Takeaways for Long-Term InvestorsKey PointsAzurity's distribution network reaches more than 1,700 leading U.S. hospitals.Nasdaq
- PolyPid Highlights D-PLEX100 Regulatory Progress, Reports Narrower Q3 Loss; Stock Up(RTTNews) - PolyPid (PYPD) reported third-quarter 2026 results while outlining progress for D-PLEX100, its lead candidate for the prevention of surgical site infections, while introducing a new…NasdaqPYPD, DDS
- PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsD-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations OngoingGlobeNewswire
- Biotech Stocks Facing FDA Decision In November 2026(RTTNews) - The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.NasdaqAGIO, BBIO, CAPR, COGT
- PolyPid Ltd. Introduces PD01B and Outlines D-PLEX₁₀₀ MilestonesPolyPid Ltd. unveiled its expanded pipeline strategy, introducing PD01B, a new product candidate targeting hyper-localized, controlled-release antibiotic treatment of diabetic foot infections. Based…Nasdaq
- PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026Analysis demonstrates a lower bacterial burden in breakthrough surgical-site infections, with similar proportions of multidrug-resistant organisms between treatment groups Analysis demonstrates a…GlobeNewswire
- PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026Management to outline ‘PolyPid 2030’, the Company’s long-term vision and pipeline strategyGlobeNewswire